Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-PanTumor02: Dato-DXd in Chinese Patients With Advanced Solid Tumours
NCT05460273Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), solid tumor, sponsored by AstraZeneca. Started Jul 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT05460273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460273.